iRhythm Raises 2026 Revenue Guidance Following Strong Q3 Performance
iRhythm (IRTC) reported third-quarter revenue of $221.6 million, representing a nearly 15% increase year-over-year. The company's core Zio Monitor business exceeded internal expectations, driving the quarterly growth despite flat performance from its Zio AT product line. Building on this momentum, management raised its full-year 2026 revenue outlook to a range of $890 million to $895 million. Looking toward long-term expansion, the company also announced plans to file for FDA approval of its Zio MCT technology in 2027.
Tickers: $IRTC
Topics: earnings quarterly results revenue growth